Ишемический инсульт: динамика клинических и нейровизуализационных показателей, система гемостаза и мозговой кровоток в остром и восстановительном периодах, лечение и профилактика повторного инсульта
Диссертация
Антиагрегантная терапия должна проводиться наряду с обязательной коррекций артериального давления, устранения имеющихся потенциально модифицируемых факторов сердечно-сосудистого риска. Комбинация ацетилсалициловой кислоты и дипиридамола может применяться у больных, перенесших инсульт, вне зависимости от уровня артериального давления и является эффективным средством вторичной профилактики… Читать ещё >
Список литературы
- Атарщикова М.В. Клопидогрель (плавике) снижает риск развития ишемических осложнений у больных с атеросклерозом. Журн. невропатол. и психиатр. Инсульт 2001- 1: 58−63.
- Бойко А.Н., Кабанов А. А., Еськина Т. А. и соавт. Эффективность. фезама у больных с хроническими формами нарушения мозгового кровообращения. Журнал неврол. и психиатр. 2005: 9: 11- 36−41.
- Верещагин Н.В., Варакин Ю. Я. Регистры инсульта в России: результаты и методологические аспекты проблемы. Инсульт 2001- 1: 34−40.
- Виленский B.C., Одинак М. М., Широков Е. А., Вознюк И. А. и др. Опыт эндолюмбальной аппликации церебролизина при полушарном ишемическом инсульте. Журн неврол и психиатр Корсакова 2000−100(11):31−34.
- Воробьев П.А., Вялков А. И., Якимов О. С. и др. В кн.: Фармакоэкономика в России. Первый опыт: М.: Ронк-Пуленк Рорер, 1998, с. 7−9.
- Всероссийское научное общество кардиологов (ВНОК) Национальные рекомендации по диагностике и лечению артериальной гипертензии. 2001.
- Гехт А.Б., Бурд Г. С., Селихова М. В. и соавт. Нарушения мышечного тонуса и их лечение сирдалудом у больных в раннем восстановительном периоде ишемического инсульта. Журн. неврол. и психиатр. 1998- 98- 10: 22−29.
- Гехт А.Б., Боголепова А. Н., Сорокина И. Б. Депрессия после инсульта: опыт применения ципрамила. Журнал неврологии и психиатрии им. Корсакова. 2002- 5: 36−39.
- Гехт А.Б. Лечение инсульта в восстановительном периоде -применение Церебролизина. IY Международный Симпозиум «Церебролизин: фармакологические эффекты и место в клинической практике». Москва 2002. С 46−55.
- Гехт А.Б. Ишемический инсульт: вторичная профилактика и основные направления фармакотерапии в восстановительном периоде. Cohsilium medicum, 2003- 5: 227−232.
- Гусев Е.И., Гехт А. Б., Гаптов В .Б., Тихопой Е. В. Реабилитация в неврологии. Учебн. пособие. М., 2000.
- Гусев Е.И., Коновалов А. Н. и соавт. Функциональная диагностика в клинике нервных болезней. 2000, 221 с.
- Гусев Е.И., Скворцова В. И. Ишемия головного мозга. М., 2001. 327 с.
- Гусев Е.И., Мартынов М. Ю., Ясаманова А. Н. и др. Этиологические факторы и факторы риска хронической сосудистой мозговой недостаточности и ишемического инсульта. Журн. неврологии и психиатрии- 2001- № 2- Приложение Инсульт 1.
- Гусев Е.И., Скворцова В. И., Стаховская JI.B. Эпидемиология инсульта в России. Ж. неврол. и психиатр, им. С. С. Корсакова, 2003- 8: 4−9.
- Гусев Е.И., Белоусов Ю. Б., Бойко А. Н. соавт. Общие принципы проведения фармакоэкономических исследований в неврологии: Метод, рекомендации. М.- Издатель Е. Разумова, 2003.-56 с. 2003.
- Гусев Е.И., Камчатнов П. Р. Пластичность нервной системы. Ж. неврол. и психиатр, им. С. С. Корсакова, 2004- 8: 54−61.
- Дамулин И.В. Постинсультные двигательные расстройства. Consilium Medicum 2003: 12: 4: 43−48.
- Иоселиани Д. Г. Диагностика и тактика ведения больных с артериальной гипертонией. М., 2002.
- Кадыков А.С., Черникова JI.A., Калашникова JI.A., Шахпаронова Н. В. Ранняя реабилитация больных с нарушениями мозгового кровообращения. Невролог, журн. 1997: 1- 24−27.
- Кобина С. А. Экономика здравоохранения. Введение в фармакоэкономику. Ремедиум. 1999, с. 38−44.
- Котляр Б.И. Нейробиологические основы обучения. М. «Наука». 1989. 238 с.
- Малкова А.А. К характеристике регистра мозгового инсульта в Ижевске: Автореф. дис. канд. мед. наук. 1998.
- Мартынов М.Ю. Ишемический инсульт у больных с дисциркуляторной энцефалопатией. Авт. дисс. доктора мед наук. М., 1995.
- Мартынов М.Ю., Бойко А. Н., Петухов Е. Б. и др. Применение эпросартана мезилата для контроля уровня артериального давления у больных с ишемическим инсультом. Журн. невропатол. и психиатр., 2002- 4: 26−30.
- Оганов Р.Г. Проблема контроля артериальной гипертонии среди населения. Кардиология 1994- 3:80−3.
- Оганов Р.Г. Профилактическая кардиология: от гипотез к практике. Кардиология 1999−39:2:4−9.
- Оганов Р. Г., Марцевич С. Ю. Лекарственная терапия сердечнососудистых заболеваний: данные доказательной медицины и реальная клиническая практика. Российский кардиологический журнал 2001−4:8−11.
- Ощепкова Е.В., Цагареишвили Е. В., Рогоза А. Н. Самоконтроль артериального давления пациентами повышает приверженность к лечению артериальной гипертонии (наблюдение 1 год) Consilium Medicum Артериальная гипертензия 2004: 6: 2- 12−18.
- Савенков М.П. Пути повышения эффективности лечения больных артериальной гипертонией. Consilium Medicum. Артериальная гипертензия 2005: 5: 7- 41−48.
- Селезнев А. Н., СтулинИ. Д., Козлов С. А., Савин А. А. Патогенетическая терапия при синдроме позвоночной артерии: методическое пособие по применению новых методов лечения. М: ММСИ, 1997 е., 42.
- Скворцова В.И. Церебролизин в лечении острого ишемического инсульта. IY Международный Симпозиум «Церебролизин: фармакологические эффекты и место в клинической практике». Москва, 2002. С 28−35.
- Скворцова В.И., Чазова И. Е., Стаховская J1.B. Вторичная профилактика инсульта. М.: ПАГРИ, 2002, 118 с.
- Скворцова В.И., Стаховская JI.B., Айриян Н. Ю. Эпидемиология инсульта в Российской Федерации Consilium Medicum. Приложение Системные гипертензии 2005- 07: 1. 32−36.
- Стулин И.Д., Мусин Р. С., Мнушкин А. О. и соавт. Клинико-инструментальная диагностика смерти мозга Атмосфера. Нервные болезни 2002: 2- 32−38.
- Суслина З.А., Танашян М. М. Антиагрегантная терапия при ишемических цереброваскулярных заболеваниях. Пособие для практикующих врачей. М., 2003- с. 166.
- Суслина 3. А., Варакин Ю. Я., Верещагин Н. В. Сосудистые заболевания головного мозга: Эпидемиология. Основы профилактики: для врачей. МЕДпресс-информ. 2006- 278 с.
- Ушакова С.Е., Концевая А. В., Княжевская О. В. и соавт. Эффект терапевтического обучения пациентов с артериальной гипертонией на приверженность лечению. Кардиоваскулярная терапия и профилактика 2005: 1- 45−51.
- Фейгин B.JI. Эпидемиология и профилактика цереброваскулярных заболеваний в Сибири: Автореф. дис.. д-ра мед. наук. М., 1991.
- Шальнова С.А. Факторы риска сердечно-сосудистых заболеваний и показатели ожидаемой продолжительности жизни населения России. Автореф. дис. док. мед. наук. М. 1999, 46 с.
- Шальнова С.А., Деев А. Д., Вихирева О. В. и др. Распространенность артериальной гипертонии в России: информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья 2001- 2:3−7.
- Шахнович А.Р., Шахнович В. А. Ультразвуковая допплерография 2001.
- Шишкин С.В. Заболеваемость и факторы риска транзиторных ишемических атак в Новосибирске: популяционное эпидемиологическое исследование: Автореф. дис. канд. мед. наук. Новосибирск, 1999.
- Щелчкова И.С. Эпидемиология инсульта в городе Краснодаре (по данным регистра). Автореф. дис. канд. мед. наук. М., 2001.
- Adams Н.Р. Jr., Kapelle L.J., Biller J., Gordon D.L., Love B.B., Gomez F., Heffner R.N. Ischemic stroke in young adults: experience in 329 patients in the Iowa Registry of Stroke in Young Adults. Arch Neurol. 1995- 52: 491−495.
- Aguilar M., Hart R. G. Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No Previous History of Stroke or Transient Ischemic Attacks. Stroke 2006−37−274−275-
- Albers G., Amarenco P., Easton D., Sacco R. L. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. CHEST 2001- 119:300S-320S.
- Algra A., van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J. Neurol Neurosurg Psychiatry 1999- 66: 255
- Anderson C.S., Jamrozik K.D., Burvill P.W., Chakera T.M.H., Johnson G.A., Stewart-Wynne E.G. Determining the incidence of different subtypes of stroke: results from the Perth Community Stroke Study, 1989−1990. Med. J. Aust. 1993−158:85−89.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002−324:71−86.
- Arnesen H. WARIS-II (Warfarin-Aspirin Re-Infarction Study) Presented at the 23 d Congress of the European Society of Cardiology, Stockholm, Sweden, 2001.
- Arrich J. Lalouschek W. Miillner M. Influence of Socioeconomic Status on Mortality After Stroke. Retrospective Cohort Study Stroke 2005−36:310−617.
- Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003−21:707−716.
- Bachman D.S. Discontinuing chronic aspirin therapy: another risk factor for stroke? Ann Neurol 2002−51:137−178.
- Becker K.J. Targeting the central nervous system inflammatory response in ischemic stroke. Curr. Opin. Neurol. 2001:14:349−353.
- Bernick C., Kuller L., Dulberg C. Silent MRI infarcts and the risk of future stroke: the Cardiovascular Health Study. Neurology 2001−57: 1222−1229.
- Bezerra D.C., Bogousslavsky J. Antiplatelets in Stroke Prevention: The MATCH Trial. Some Answers, Many Questions and Countless Perspectives. Cerebrovasc Dis 2005- 20(suppl 2): 109−118.
- Bhatt D., Foody J., Hirsch A., Ringleb P., Hacke W., Topol E. Complementary, additive benefi t of clopidogrel and lipid-lowering therapy in patients with atherothrombosis. J Am Coll Cardiol 2000- 35(suppl A):326.
- Bhatt D., Chew D., Hirsch A., Ringleb P., Hacke W., Topol E. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001- 103:363−368.
- Bhatt D.L., Marso S.P., Hirsch A.T., Ringleb P.A., Hacke W., Topol E.J. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am. J. Cardiol. 2002−90:625−628.
- Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000−355:1955−64.
- Boado RJ, Wu D, Windisch M. In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides. Neurosci Res 1999- 34(4):217−224.
- Bogaert L, Scheller D, Moonen J, Sarre S, Smolders I, Ebinger G, Michotte Y. Neurochemical changes and laser Doppler flowmetry in the endothelin-1 rat model for focal cerebral ischemia. Brain Res. 2000−887(2):266−275.
- Bonita R., Anderson C.S., Broad J.B., Jamrozik K.D., Stewart-Wynne E.G., Anderson N.E. Stroke incidence and case fatality in Australasia: a comparison of the Auckland and Perth population-based stroke registers. Stroke. 1994−25:552−557.
- Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ. Role { of IL-1 alpha and IL-lbeta in ischemic brain damage. J Neurosci 2001−21 (15):5528−5534.
- Bravata D., Rosenbeck K., Kancir S., Brass L. The use of warfarin in veterans with atrial fibrillation BMC Cardiovascular Disorders 2004, 4:18−24.
- Brouwer M. APRICOT-2 (Antithrombotics in the Prevention of Reocclusion in COronary Thrombolysis). Presented at the 22nd Congress of the European Society of Cardiology, Amsterdam, The Netherlands, 2000.
- Brown R.D., Petty G.W., O’Fallon W.M., Wiebers D.O., Whisnant J.P. Incidence of transient ischemic attack in Rochester, Minnesota, 1985−1989. Stroke. 1998- 29:2109−2113.
- Brown D., Lisabeth L., Roychoudhury C. Recurrent Stroke Risk Is Higher Than Cardiac Event Risk After Initial Stroke/Transient Ischemic Attack. Stroke 2005−36:676−681.
- Bruno A.A. Motor recovery in stroke. In: Physical Medicine and Rehabilitation. M.J.Klein et al. (eds.). Medicine, 2002.
- Buchanan M.R., Brister S.J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995 11:221−227.
- Burn J., Dennis M., Bamford J., Sandercock P., Wade D., Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994−25:333−337.
- Camerlingo M., Casto L., Censori В., Ferraro В., Caverni L., Manara O., Finazzi G. Recurrence after first cerebral infarction in young adults Acta Neurologica Scandinavica 2000- 102- 2−87−92.
- Capizzano A. A., Schuff N., Amend D. L. et al. Subcortical ischemic vascular dementia: assessment with quantitative MR imaging and 1H MR spectroscopy. American Journal of Neuroradiology. 2000−21(4):621−630.
- CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996- 348: 1329−1339.
- Carey L.M., Abbott D.F., Puce A. et al. Reemergence of activation with poststroke somatosensory recovery: a serial fMRI case study. Neurology 2002- 59: 749−752.
- Carolei A., Marini C., Di Napoli M., Di Gianfilippo G., Santalucia P., Baldassarre M., De Matteis G, Di Orio F. High stroke incidence in the prospective community-based L’Aquila registry (1994−1998). First year’s results. Stroke 1997- 28: 2500−2506.
- Castillo J., Davalos A., Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet: 1997: 349- 79−83.
- Chalmers J. Trials on blood pressure-lowering and secondary stroke prevention American Journal of Cardiology 2003- 91- 10- Supp. 1: 3−8.
- Chaturvedi N., Sjolie A.-K., Stephenson J.M. et al. and the EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998−351:28−31.
- Chen H., Tung Y., Li В., Iqbal K., Grundke-lqbal I. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol. Aging. 2006- 45: 121−129.
- Chan F.K., Ching J.Y., Hung L.C. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005- 352(3): 238−44.
- Clemens J. A. Cerebral ischemia: gene activation, neuronal injury, and the protective role of antioxidants. Free Radic Biol Med 2000−28(10): 1526−1531
- Cohen N., Almoznino-Sarafian D., Alon I., Gorelik O., Koopfer M., Chachashvily S., Shteinshnaider M., Litvinjuk V., Modai D. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000, 31: 1217−1222.
- Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001- 357: 89−95.
- Collins R., Mac Mahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull 1994−50:272−298.
- COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005- 366: 1607−1621.
- Craig J., Goudie B. Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. Scottish Medical Journal 2000- 45: 110−112.
- CURE Study Investigators. Effects of clopidogrel in addition to aspirin in patients with non-ST segment elevation acute coronary syndromes. N Engl J Med 2001−345:494−502
- D’Alessandro G., Di Giovanni M., Roveyaz L., Ianizzi L., Compagnoni M.P., Blanc S., Bottacchi E. Incidence and prognosis of stroke in the Valle d’Aosta Italy. Stroke. 1992−23:1712−1715.
- Darius H, Bertrand-Hardy JM, Humphreys M- European Stroke Prevention Study 2. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001 -55(3): 162−3.
- Del Zoppo, G., Ginis, I., Hallenbeck, J.M., Iadecola, C., Wang, X., and Feuerstein, G.Z. Inflammation and stroke: Putative role for cytokines, adhesionmolecules and iNOS in brain response to ischemia. Brain Pathol. 2000: 1: 95 112.
- Dennis M., Bamford J., Sandercock P., Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990- 21: 848−853.
- De Schryver E., Algra A., van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database SystRev. 2006-(2):CD001820.
- Di Bari M., Pahor M., Franse L.V., Shorr R.I., Wan J.Y., Ferrucci L. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am J Epidemiol. 2001- 153: 72−78.
- Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996- 143(1−2): 1−13.
- Dijkhuizen R.M., Ren J.-M., Mandeville J.B. et al. Functional magnetic resonance imaging of reorganization in rat brain after stroke. Proc. Natl. Acad. Sci. 2001:98- 12 766−12 771.
- Dirnagl U., Simon R.P., and Hallenbeck J.M. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003- 26:248−254.
- Dobkin B.H., Thompson A.J. Principles of Neurological Rehabilitation. In: Neurology in Clinical Practice. W.G.Bradley et al. (eds.). Chapter 54. Butterworth-Heinemann, 2000.
- Dyker A., Lees K. Duration of neuroprotective treatment for ischemic stroke. Stroke 29:535−542, 1998.
- Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med. 2003- 254: 95−101.
- Eidelman RS, Hebert PR, Weisman SE, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003−163:2006−2010.
- Elkind M. The role of warfarin and aspirin in secondary prevention of stroke. Curr Cardiol Rep. 2004- 6(2): 135−42.
- Ellekjor H., Holmen J., Indredavik В., Terent A. Epidemiology of stroke in Innherred, Norway, 1994−1996. Incidence and 30-day case-fatality rate. Stroke 1997−28:2180−2184.
- Endres M., and Dirnagl U. Ischemia and stroke. Adv. Exp. Med. Biol. 2002: 513:455473.
- ESPRIT Study Group- Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006- 367(9523): 1665−73.
- Estacio R.O., Schier R.W. Antihypertensive therapy in type 2 diabetes: implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am J Cardiol 1998−82:9R—14R.
- Expert Consensus Document on the use of antiplatelet agents. The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur. Heart J. 2004- 25:166−81.
- Fazekas F., Kapeller P., Schmidt R. et al. The relation of cerebral magnetic resonance signal hyperintensities to Alzheimer’s disease. J Neurol Sci 1996−142:121−125.
- Feigenson J.S. Neurological Rehabilitation. In: Baker’s Clinical Neurology. R.J.Joynt et al. (eds.) Philadelphia: Lippincott Williams & Wilkins, 1999.
- Felmeden D. C., Lip G. Y. H. Antithrombotic therapy in hypertension: a Cochrane Systematic review. Journal of Human Hypertension 2005: 19- 185 196.
- Felmeden D., Nadar S. K., Lip G. Y. H. Aspirin and endothelial function in hypertension. Journal of Human Hypertension 2005- 19: 663−665.
- Ferrer I., Planas A.M. Signaling of cell death and cell survival following focal cerebral ischemia: Life and death struggle in the penumbra. J. Neuropathol. Exp. Neurol. 2003- 62:329−339.
- Ferro D., Parrotto S., Basili S., Alessandri C., Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000- 36: 427−31.
- Fiore L.D. Primary Results of the CHAMP Study. Circulation. 2002−105:557−563.
- Friday G., Alter M., Lai S.M. Control of hypertension and risk of stroke recurrence. Stroke 2002−33:2652−2657.
- Gage В., van Walraven С., Pearce L., Hart R., Koudstaal P., Boode В., Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004- 110: 2287−2292.
- Gentile M., Fassetta G., Casetta I., Agnoli F., Andreotta G., Barp C., Caneve G. Incidence and prognosis of stroke in the Belluno province, Italy. First-year results of a community-based study. Stroke 1995- 26: 1787−1793.
- Gill R., Soriano M., Blomgren K., Hagberg H., Wybrecht R., Miss M., Hoefer S. Role of caspase-3 activation in cerebral ischemia-induced neurodegeneration in adult and neonatal brain. J. Cereb. Blood. Flow. Metab. 2002- 22(4): 420−430.
- Ginsberg M.D. Adventures in the pathophysiology of brain ischemia: Penumbra, gene expression, neuroprotection: The 2002 Thomas Willis Lecture. Stroke 2003- 34:214−223.
- Gladstone D., Black S., Hakim A. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33:2123−2136, 2002.
- Godbout C.J., Johns J.S. Stroke motor impairment. In: Physical Medicine and Rehabilitation. P.J.Potter et al. (eds.). Medicine, 2002.
- Golding E. M., Vink R. Efficacy of competitive vs noncompetitive blockade of the NMDA channel following traumatic brain injury. Mol. Chem. Neuropathol. 1995- 24: 137−150.
- Goldstein L. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. Stroke. 1998- 29:1602−1604.
- Gorelick P. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls. Lancet 355:1925−1926, 2000.
- Grau A., Reis A, Buggle F., Al-Khalaf A., Werle E., Valois N., Bertram M. et al. Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. J Neurol Sci 2001- 192(1−2): 41−47.
- Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb. Res. 1991- 63:587−593.
- Grundmann K., Jaschonek K., Kleine В., Dichgans J., Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003- 250:63−66.
- Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001- 88:230−235.
- Gutman В., Hutter-Paier В., Skofitsch G., Windisch M., Gmeinbauer R. In vitro models of brain ischemia: the peptidergic drug Cerebrolysin protects chick cortical neurons from cell death. Neurotoxity Res 2002- 4(l):59−65.
- Hayden M., Pignone M., Phillips C., Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002- 136: 161−72.
- Hallett M. Plasticity of the human motor cortex and recovery from stroke. Brain Res. Rev. 2001: 36- 169−174.
- Hankey G.J., Jamrozik K., Broadhurst R.J., et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998−29: 24 912 500.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998−351:1755−62. 6.
- Hart R.G., Halperin J.L., McBride R., Benavente O., Man-Son-Hing M., Kronmal R.A. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000−57(3):326−32.
- Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of HOPE study and MICRO-HOPE substudy. Lancet 2000−355: 253—259.
- Hengartner M.O. The biochemistry of apoptosis. Nature 2000- 407:770 776.
- Hill M.D., Yiannakoulias N., Jeerakathil Т., Tu J.V., Svenson L.W., Schopflocher D. P. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology. 2004−62: 2015−2020.
- Hillen Т., Coshall C., Tilling K.5 Rudd A. G., McGovern R., Wolfe C. D. A. Cause of Stroke Recurrence Is Multifactorial Patterns, Risk Factors, and
- Outcomes of Stroke Recurrence in the South London Stroke Register Stroke. 2003−34:1457.
- Haffner Z, Javor L, Windisch M, Gmeinbauer R. Cerebrolysin in acute ischemic stroke. Cephallag Hungr 1999−5:52−53.
- Hopman W., Verner J. Quality of Life During and After Inpatient Stroke Rehabilitation. Stroke. 2003−34:801−806.
- Horvathova H., Kimlikova K., Balazovjech I., Kyselovic I. Compliance and the therapeutic effect in patients with arterial hypertension. Bratisl Lek Listy 2003- 104 (4−5): 149−54.
- International Stroke Trials Collaborative Group. 1ST: a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997−349: 1569−81.
- Irie K., Yamaguchi Т., Minematsu K., Omae T. The J-curve phenomenon in stroke recurrence. Stroke 1993- 24: 1844—1849.
- Jencks S.F., Cuerdon Т., Burwen D.R., Fleming В., Houck P.M., Kussmaul A.E., Nilasena D.S. Quality of Medical Care Delivered to Medicare Beneficiaries: A Profile at State and National Levels. JAMA 2000- 284: 16 701 676.
- Johansson B.B. Brain plasticity and stroke rehabilitation. The Willis Lecture. Stroke- 2000: 31: 223−230.
- Johnson C.J., Kittner S.J., McCarter R.J., Sloan M.A., Stern B.J., Buchholz D., Price T.R. Interrater reliability of an etiologic classification of ischemic stroke. Stroke. 1995−26:46−51.
- Johnson E., Lanes S., Wentworth С. Ill, Satterfield M., Abebe Dicker L. A metaregression analysis of the dose-response effect on stroke. Arch. Intern. Med. 1999- 159(11): 1248−53.
- Johnston S.C., Gress D.R., Browner W.S., Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000- 284: 2901−2906.
- J0rgensen H.S., Plesner A.-M., Hiibbe P., Larsen K. Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg, Denmark. Stroke. 1992- 23:1701−1704.
- Kahraman G., Sahin Т., Kilic T. et al. The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. International Journal of Cardiology 2007- 115: 3:391−396.
- Kang D.W., Latour L.L., Chalela J.A., Dambrosia J., Warach S. Early ischemic lesion recurrence within a week after acute ischemic stroke. Ann. Neurol. 2003- 54:66−74.
- Kang S., Wu Y., Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 2004- 177- 2: 433−442.
- Katzan I., Cebul R., Husak S., Dawson N., Baker D. The effect of pneumonia on mortality among patients hospitalized for acute stroke. Neurology. 2003 Feb 25- 60(4): 620−5.
- Kirkham F., Hogan A. Risk factors for arterial ischemic stroke in childhood. CNS Spectr. 2004- 9(6):451−64.
- Kleindorfer D., Panagos P., Pancioli A., Khoury J., Kissela В., Woo D., Schneider A., Alwell K., Jauch E. et al. Incidence and Short-Term Prognosis of Transient Ischemic. Attack in a Population-Based Study Stroke. 2005−36:218−224.
- Ко D. Т., Mamdani M., Alter D. A. Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients. The Treatment-Risk Paradox. JAMA. 2004- 291: 1864−1870.
- Kolb B. Brain plasticity and behavior. Annual Review of Psychology, 1998.
- Koppi S., Barolin G. Hemodilution therapy with neuron metabolism specific therapy in ischemic stroke encouraging results of a comparative study. Wien Med Wochenschr 1996−146(3):41−48.
- Kristensen В., Malm J., Carlberg B. Epidemiology and Etiology of Ischemic Stroke in Young Adults Aged 18 to 44 Years in Northern Sweden. Stroke. 1997- 28: 1702−1709.
- Ladurner G., Gmeinbauer R., Moessler H. Cerebrolysin in acute ischemic stroke: a randomized, placebo-control- led clinical trial with a neuroprotective agent. 10-th Europ Stroke Confer Lisbon Portugal: Cer Dis 2001- 1 l (supp 4):75.
- Ladurner G., Kalvach P., Moessler H. Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission 2005- 112: 3: 415−428
- Lai S.M., Alter M., Friday G., Sobel E. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke 1994−25:958−962.
- Langhorne P., Stott D.J., Robertson L. et al. Medical complication after stroke: A multicenter study. Stroke. 2000: 31- 1223−1229.
- Lemesle M., Milan C., Faivre J., Moreau Т., Giroud M., Dumas R. Incidence trends of ischemic stroke and transient ischemic attacks in a well-defined french population from 1985 through 1994. Stroke. 1999- 30: 371−377.
- Lenz Т., Hilleman D. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother. 2000- 34(11): 1283−1290.
- Liepert J., Bauder H., Miltner W.H.R. et al. Treatment-induced cortical reorganization after stroke in humans. Stroke. -2000. -Vol.31. -P.1210−1216
- Lokkegaard E., Jovanovic Z., Heitmann L. Et al. Increased Risk of Stroke in Hypertensive Women Using Hormone Therapy. Analyses Based on the Danish Nurse Study Arch Neurol. 2003−60:1379−1384.
- Lovett J. К., Coull A. J., Rothwell P. M. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004- 62: 569−573.
- Law M.R. Epidemiological evidence on salt and blood pressure. Am J Hypertens 1997- 10: Suppl: 42S—45S.
- Law M.R., Wald N.J. Risk factor thresholds: their existence under scrutiny BMJ 2002- 324:1570−6.
- Lo E.H., Dalkara, Т., and Moskowitz, M.A. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 2003- 4:399−415.
- Numminen H., Kotila M., Waltimo O., Aho K., Kaste M. Declining incidence and mortality rates of stroke in Finland from 1972 to 1991. Results of three population-based stroke registers. Stroke 1996−27:1487−1491.
- Manson J., Hsia J., Johnson K. et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003−349: 523−34.
- Marshall R.S., Perera G.M., Lazar R.M. et al. Evalution of cortical activation during recovery from corticospinal tract infarction. Stroke: 2000: 31- 656−661.
- Matsumoto K., Lo E. H., Pierce A. R., Halpern E. F., Newcomb R. Secondary elevation of extracellular neurotransmitter amino acids in the reperfusion phase following focal cerebral ischemia. J. Cereb. Blood Flow Metab. 1996. — Vol. 16. — P. 114−124.
- Medin J., Nordlund A., Ekberg K. Increasing Stroke Incidence in Sweden Between 1989 and 2000 Among Persons Aged 30 to 65 Years: Evidence From the Swedish Hospital Discharge Register Stroke. 2004−35:1047.
- Meins W., Meier-Baumgartner H.-P., Neetz D., von Renteln-Kruse W. Predictors of favorable outcome in elderly stroke patients two years after discharge from geriatric rehabilitation. Z. Gerontol. Geriatr. 2001: 34- 395−400.
- Molteni R., Ying Z., Gomez-Pinilla F Differential effects of acute and chronic exercise on plasticity-related genes in the rat hippocampus revealed by microarray. European Journal of Neuroscience 2002- 16- 6: 1107−1114.
- Montaner J., Alvarez-Sabin J., Barbera G., Angles A., Molina C., Abilleira S. Correlation between the expression of proinflammatory cytokines and matrix metalloproteinases in the acute phase of an ischemic stroke. Rev Neurol 2001- 33(2): 115−118.
- Montgomery P., Berger L., Mitenko P., Sitar D. Salicylate metabolism: effects of age and sex in adults. Clin Pharmacol Ther 1986−39:571−576.
- Mosca L, Appel L., Benjamin E. et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004- 109:672−93.
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. The Lancet 2002- 360:7−22.
- Muellbacher W., Artner C., Mamoli B. The role of the intact hemisphere in recovery of midline muscles after recent monohemispheric stroke. J. Neurol. 1999:246- 250−256.
- Muller T. Inhibition of thrombus formation by low-dose acetylsalicylic acid, dipyridamole, and their combination in a model of platelet-vessel wall interaction. Neurology. 2001- 57(5 Suppl 2):S8-S11
- Nakamura Т., Uchiyama S., Yamazaki M., Iwata M. Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Cerebrovasc Dis. 2002- 14(3−4):234−238.
- Nelles G., Spiekermann G., Jueptner M. et al. Reorganization of sensory and motor systems in hemiplegic stroke patients: A positron emission tomography study. Stroke. 1999- 30: 1510−1516.
- Netz J., Lammers Т., Homberg V. Reorganization of motor output in the non-affected hemisphere after stroke. Brain. 1997- 120: 1579−1586.
- Nightingale A., Farmer R. Ischemic Stroke in Young Women. A Nested Case-Control Study Using the UK General Practice Research Database. Stroke. 2004- 35: 1574−1580.
- Obrenovitch T. P., Urenjak J. Altered glutamatergic transmission in neurological disorders: from high extracellular glutamate to excessive synaptic efficacy. Progr. Neurobiol. 1997: 51- 39−87.
- Ovbiagele В., Kidwell C. S., Saver J. L. Expanding Indications for Statins in Cerebral Ischemia A Quantitative Study Arch Neurol. 2005- 62: 67−72.
- Palmer A. M., Marion D. W., Botscheller M. L., Bowen D. M., DeKosky S. T. Increased transmitter amino acid concentration in human ventricular CSF after brain trauma. Neuroreport. 1994- 6: 153−156.
- Persell S., Baker D. Aspirin underused in patients with diabetes. Arch. Intern. Med. 2004- 164: 2492−2499.
- Pessah-Rasmussen H., Engstrom G., Jerntorp I., Janzon L. Increasing Stroke Incidence and Decreasing Case Fatality, 1989−1998. A Study From the Stroke Register in Malmo, Sweden Stroke. 2003- 34: 913−919.
- Peterson J.C., Adler S., Bukart J.M. et al. For the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control, proteinuria and progression of renal disease. Ann Intern Med 1995- 123:754—762.
- Peto R., Gray R., Collins R. et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J. (Clin Res Ed) 1988- 296:313−316.
- Petty G.W., Brown R.D.J., Whisnant J.P., Sicks J.D., O’Fallon W.M., Wiebers D.O. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998−50:208−216.
- Poggio E.D., Kotke-Marchant K., Welsh P.A., Brooks L.M., De la Rosa L.R., Topol EJ. The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and the PFA-100. J Am Coll Cardiol. 1999- 33:1104−1168.
- Pohjasvaara Т., Vataja R., Leppavuori A. et al. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur. J. Neurol. 2001: 8- 315−319.
- Posada I., Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J. 1999−138:137−143.
- PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens 1996−14:Suppl 2: S41—S46.
- PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001- 358: 1033−1041.
- Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 45,000 people in 45 prospective cohorts. Lancet 1995- 346: 1647−1653.
- Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002−360:1903−13.
- Provinciali L., Coccia M. Post-stroke and vascular depression: a critical review. Neurol. Sci. 2002: 22- 417−428.
- Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. PROGRESS Collaborative Group. Lancet 2001−358:1033−1041.
- Ringleb P., Bhatt D., Hirsch A., Topol E., Hacke W. Benefi t of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004- 35: 528−532.
- Rockenstein E., Mante M., Adame A., Crews L., Moessler H., Masliah E. Effects of Cerebrolysin trade mark on neurogenesis in an APP transgenic model of Alzheimer’s disease. Acta Neuropathol (Berl). 2007- 113(3): 265−275.236.
- Rosenson R., Tangney C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J Am Med. Assoc. 1998- 279: 1643−50.
- Rosenson R. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004: 173- 1−12.
- Roth E.J., Lovell L., Harvey R.L. et al. Incidence of and risk factors for medical complications during stroke rehabilitation. Stroke 2001: 32- 523−529.
- Rothwell P.M., Coull A.J., Giles M.F., Howard S.C., Silver L.E., Bull L.M. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in
- Oxfordshire, UK from 1981 to 2004 (Oxford vascular study). Lancet 2004- 363: 1925−1933.
- Rutgers D.R., Klijn C., Kappelle L.J. et al. Recurrent Stroke in Patients With Symptomatic Carotid Artery Occlusion Is Associated With High-Volume Flow to the Brain and Increased Collateral Circulation Stroke. 2004- 35: 13 451 349.
- Sacco R.L., Foulkes M.A., Mohr J.P., Wolf P.A., Hier D.B., Price T.R.. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank.1. Stroke 1989−20:983−989.
- Sacco R.L., Shi Т., Zamanillo M.C., Kargman D.E. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994- 44: 626−634.
- Sakai M., Kobori S, Matsumura T. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997- 133:51−59.
- Sandercock P., Gubitz G., Counsell C. Anticoagulants for Acute Ischemic Stroke. Stroke. 2004−35:2916−2917.
- Sastry S., Riding G., Morris J., Taberner D., Cherry N., Heagerty A. Young Adult Myocardial Infarction and Ischemic Stroke The Role of Paradoxical Embolism and Thrombophilia (The YAMIS Study). J Am Coll Cardiol, 2006- 48:686−691.
- Saxena R., Lewis S., Berge E. et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001−32:2333−2337.
- Saxena R., Koudstaal P. J. Anticoagulants for Preventing Stroke in Patients With Nonrheumatic Atrial Fibrillation and a History of Stroke or Transient Ischemic Attack Stroke. 2004- 35: 1782−1783.
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994- 344: 1383−1389.
- Shah H., Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. Clin Ther. 2000- 22(3): 362−370.
- Shin C., Chung Y., Kim M. Spatial and temporal distribution of pituitary adenylate cyclase activating polypeptide in gerbil global cerebral ischemia. Neurosci Lett 2001- 309(l):53−56
- Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 1989- 321:129−35.
- Stiegler H., Fischer Y., Niederau С., Schoebel F.C., Borries M., Strauer B.E., Leschke M., Reinauer H. Evidence for variable platelet response to low-dose ASA in patients with coronary artery disease. J Am Coll Cardiol. 1999- 33:1104−1168.
- Smadja D., Cabre P., May F., Fanon J.L., Reny-Corail P., Riocreux C. and the ERMANCIA Study Group: ERMANCIA: Epidemiology of Stroke in Martinique, French West Indies. 1. Methodology, incidence, and 30-day case fatality rate. Stroke 2001−32:2741−2747.
- Sturm J. W., Donnan G. A., Dewey H. M., Macdonell R. A. L., Gilligan A. K., Thrift A. G. Determinants of Handicap After Stroke. The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2004−35:715−723.
- Roman G., Tatemichi Т., Erkinjutti T. et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993−43:250−260
- Terent A. Trends in stroke incidence and 10-year survival in Soderhamn, Sweden, 1975−2001. Stroke. 2003−34:1353−1358.
- The Organization to Assess Strategies for Ischemic Syndromes (OASIS) investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001−37:475−84.
- The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, CHEST 2004- 126:234S-264S, 483S-51 IS, 513S-548S, 576S-599S.
- Thrift A. G., Dewey H. M., Macdonell R. A.L., McNeil J. J., Donnan G. A. Incidence of the Major Stroke Subtypes. Initial Findings From the North East Melbourne Stroke Incidence Study (NEMESIS) Stroke. 2001−32:1732−1738.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998−317:703−713.
- Vermeer S.E., Hollander M., Van Dijk E.J., Hofman A., Koudstaal P.J., Breteler M.M. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003−34:1126−1129.
- Vernino S., Brown R. D., J. Sejvar J., Sicks J. D., Petty G. W. Cause-Specific Mortality After First Cerebral Infarction. A Population-Based Study. Stroke. 2003−34:1828.
- Vemmos K.N., Bots M.L., Tsibouris P.K., Zis V.P., Grobbee D.E., Stamatelopoulos S. Stroke incidence and case fatality in Southern Greece: the Arcadia Stroke Registry. Stroke. 1999- 30:363−370.
- Vickrey В., Rector Т., Wickstrom S., Guzy PM, Sloss EM, Gorelick PB, Garber S, McCaffrey DF, Dake MD, Levin RA. Occurrence of secondaryischemic events among persons with atherosclerotic vascular disease. Stroke. 2002- 33:901−906.
- Vole D., Adler J. Therapeutic Effects of Cerebrolysin with Stroke Patients during Rehabilitation. Euro Rehab 1998- (3−4): 19−26.
- Waeber В., Burnier M., Brunner H.R. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000- 36 (suppl. 3): S23-S26.
- Wei Z., He Q., Wang H., Su В., Chen H. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease. J Neural Transm. 2007.
- Weiller C., Rijntjes M. Leaning, plasticity, and recovery in the central nervous system. Exp. Brain. Res. 1999: 128−134−138.
- WHO-MONICA Project, Stegmayr В., Asplund K., Kuulasmaa K. et al. Stroke incidence and mortality correlated to stroke risk factors in the WHO-MONICA Project Study: en ecological study in 18 populations. Stroke 1997−28:1367−1374.
- Wilterdink J.L., Easton J.D. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch. Neurol. 1992−49:857−863.
- Wolfe C.D.A., Giroud M., Kolominsky-Rabas P., Dundas R., Lemesle M., Heuschmann P., Rudd A. for the European Registries of Stroke (EROS) Collaboration: Variations in stroke incidence and survival in 3 areas of Europe. Stroke 2000−31:2074−2079.
- Yatsu F.M., Grotta J.C., Pettigrew L.C. Stroke: 100 Maxims. St. Louis etc.: Mosby, 1995.
- Yoon S., Dambrosia J., Chalela J., Ezzeddine M., Warach S., Haymore J., Davis L., A. Baird Rising statin use and effect on ischemic stroke outcome. BMC Medicine 2004- 2:4−12.
- Zheng F., Gingrich M. В., Traynelis S. F., Conn P. J. Tyrosine kinase potentiates NMDA receptor currents by reducing tonic zinc inhibition. Nat. Neurosci. 1998: 1: 185−191.